Paper Details

  1. Home
  2. Paper Details

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Author: AhdabSamih El, BorthakurGautam, FaderlStefan, FerrajoliAlessandra, IssaJean-Pierre, KantarjianHagop, NewmanBeth, RavandiFarhad

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Decitabine is effective in treating patients with myelodysplastic syndrome (MDS) who have failed azacitidine therapy.
Paper Details　
Original Abstract of the Article :
Azacitidine and decitabine are the two hypomethylating agents approved by the Food and Drug Administration for the treatment of patients with myelodysplastic syndrome (MDS). The efficacy of one agent post-failure of the other is unknown. Fourteen patients with MDS post-azacitidine failure/lack of re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18398735

データ提供：米国国立医学図書館（NLM）

Decitabine: A Second Line of Defense Against Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) is a group of blood disorders that can lead to various complications, including anemia and an increased risk of leukemia. [Azacitidine] and [decitabine] are two medications approved for treating MDS, but the effectiveness of one after the other is not well-established. This study explores the use of decitabine in patients who have previously received azacitidine. The results show that decitabine can be effective in patients who have failed to respond to or have become intolerant to azacitidine.

Expanding Treatment Options for MDS: The Role of Decitabine

This study suggests that decitabine can be a valuable treatment option for patients with MDS who have not responded to or have become intolerant to azacitidine. The findings highlight the importance of considering decitabine as a potential alternative for these patients.

Navigating the Complexities of Blood Disorders: A Journey of Hope and Resilience

As a camel who has encountered the occasional sandstorm, I can empathize with the challenges faced by those living with MDS. This research provides a glimmer of hope by highlighting the potential of decitabine to offer a second line of defense against this complex disease.

Dr.Camel's Conclusion

This study provides encouraging data regarding the effectiveness of decitabine in patients with MDS who have previously received azacitidine. These findings highlight the importance of individualized treatment plans and offer a renewed sense of hope for patients facing this challenging disease.

Date :
  1. Date Completed 2008-08-04
  2. Date Revised 2023-02-02
Further Info :

Pubmed ID

18398735

DOI: Digital Object Identifier

NIHMS487592

Related Literature

Article Analysis
・Side Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.